Clinical Trial Update: Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase I study evaluating cetuximab in combination with RO4929097 for metastatic colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (Erbitux) (Cetuximab)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma | Phase 1 | Status: TERMINATED